Literature DB >> 15834098

Penetration of moxifloxacin into the human aqueous humour after oral administration.

G Kampougeris1, A Antoniadou, E Kavouklis, Z Chryssouli, H Giamarellou.   

Abstract

AIMS: To determine the pharmacokinetics of moxifloxacin, a new generation fluoroquinolone, in the anterior chamber of the human uninflamed eye.
METHODS: 35 patients undergoing cataract surgery received two doses of 400 mg of oral moxifloxacin with a 12 hour interval and were divided into six groups. Moxifloxacin levels in aqueous humour and serum were determined by a microbiological agar well diffusion technique at 2, 4, 6, 8, 10, and 12 hours after the second dose in each group respectively.
RESULTS: Mean moxifloxacin levels in the anterior chamber were 1.20 (SD 0.35) microg/ml at the 2 hours group, 1.22 (0.48) microg/ml at the 4 hours group, 1.20 (0.45) microg/ml at the 6 hours group, 1.58 (0.38) microg/ml at the 8 hours group, 1.37 (0.44) microg/ml at the 10 hours group, and 1.23 (0.55) microg/ml at the 12 hours group. The mean ratio of aqueous to serum moxifloxacin level was 38%.
CONCLUSION: Moxifloxacin penetrates well into the anterior chamber of the human uninflamed eye after oral administration, reaching early significant levels, which are maintained for at least 12 hours and are much higher than the MIC(90) values of Gram positive and Gram negative pathogens commonly implicated in intraocular infections with the exceptions of fluoroquinolone resistant staphylococci, MRSA, and Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834098      PMCID: PMC1772646          DOI: 10.1136/bjo.2004.050054

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  23 in total

Review 1.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  Aqueous and vitreous penetration of levofloxacin after oral administration.

Authors:  R G Fiscella; T K Nguyen; M J Cwik; B A Phillpotts; S M Friedlander; D C Alter; M J Shapiro; N P Blair; J P Gieser
Journal:  Ophthalmology       Date:  1999-12       Impact factor: 12.079

Review 3.  Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes?

Authors:  Y J Gordon
Journal:  Am J Ophthalmol       Date:  2001-03       Impact factor: 5.258

Review 4.  Evaluation of the clinical microbiology profile of moxifloxacin.

Authors:  C Krasemann; J Meyer; G Tillotson
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

Review 5.  Mechanisms of action of antimicrobials: focus on fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

6.  Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.

Authors:  M C García-Sáenz; A Arias-Puente; M J Fresnadillo-Martinez; C Carrasco-Font
Journal:  J Cataract Refract Surg       Date:  2001-12       Impact factor: 3.351

7.  Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.

Authors:  M H Goldstein; R P Kowalski; Y J Gordon
Journal:  Ophthalmology       Date:  1999-07       Impact factor: 12.079

8.  Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate.

Authors:  P Y Wong; M Zhu; R C Li
Journal:  J Chemother       Date:  2000-08       Impact factor: 1.714

9.  Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.

Authors:  Rookaya Mather; Lisa M Karenchak; Eric G Romanowski; Regis P Kowalski
Journal:  Am J Ophthalmol       Date:  2002-04       Impact factor: 5.258

10.  Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.

Authors:  R Frothingham
Journal:  Pharmacotherapy       Date:  2001-12       Impact factor: 4.705

View more
  12 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

2.  [Modification of the histopathologic degree of inflammation in asymptomatic prostatitis (NIH IV) by moxifloxacin].

Authors:  T Bschleipfer; F M E Wagenlehner; W Weidner
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

3.  Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Authors:  Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Christine Miossec; Nathalie Saint-Lu; Mark Pulse; William Weiss; Antoine Andremont; France Mentré; Jean de Gunzburg
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

Authors:  France Mentré; Jean de Gunzburg; Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Perrine Hugon; Frédérique Sablier-Gallis; Nathalie Saint-Lu; Tanguy Corbel; Stéphanie Ferreira; Mark Pulse; William Weiss; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

5.  Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin.

Authors:  María Sebastián-Morelló; María Aracely Calatayud-Pascual; Vicent Rodilla; Cristina Balaguer-Fernández; Alicia López-Castellano
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 6.  Antimicrobial guide to posterior segment infections.

Authors:  Tapan P Patel; David N Zacks; Vaidehi S Dedania
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-06       Impact factor: 3.117

7.  Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients.

Authors:  S Horster; L Bader; U Seybold; I Eschler; K G Riedel; J R Bogner
Journal:  Infection       Date:  2008-12-05       Impact factor: 3.553

Review 8.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

Review 9.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681

10.  Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.

Authors:  Darlene Miller
Journal:  Clin Ophthalmol       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.